Literature DB >> 26223917

Single nucleotide polymorphism of CYP3A4 intron 2 and its influence on CYP3A4 mRNA expression and liver enzymatic activity in human liver.

Min Huang1,2, Han-Ming Wang1, Yu Guo2, Jie Ping2,3, Man Chen2, Dan Xu2, Hui Wang4,5.   

Abstract

In adult liver, CYP3A4 plays an important role in the metabolism of a wide range of endogenous and exogenous compounds. To investigate whether there is a single nucleotide polymorphism (SNP) of CYP3A4 intron 2 in the liver and its effects on the mRNA expression and enzymatic activity of CYP3A4, genomic DNA was extracted from 96 liver tissue samples obtained from patients who had undergone liver surgery. An SNP of CYP3A4 intron 2 was identified by polymerase chain reaction (PCR)-single-strand confirmation polymorphism and DNA sequencing. The mRNA expression of CYP3A4 was determined by the fluorescence quantitative PCR technique. The enzymatic activity of CYP3A4 was measured using erythromycin and testosterone as probe substrates. Twelve patients were found to have the SNP/T4127G CYP3A4 within intron 2. The mRNA levels of CYP3A4 in wild-type and SNP/T4127G samples were 2.62±1.09 and 2.79±1.63, respectively (P>0.05). Erythromycin N-demethylase activity in wild-type and SNP/T4127G samples were 121.2±32.8 and 124.7±61.6 nmol·mg(-1)·min(-1), respectively (P>0.05). The activity of testosterone 6β-hydroxylase was significantly different between wild-type (648±173 pmol·mg(-1)·min(-1)) and SNP/T4127G samples (540±196 pmol·mg(-1)·min(-1); P<0.05). In conclusion, the SNP/T4127G of CYP3A4 intron 2 exists in the liver. This SNP does not affect the mRNA expression of CYP3A4 but significantly decreases the hepatic microsomal testosterone 6β-hydroxylase activity of CYP3A4. Furthermore, this study indicates that the appropriate selection of probe substrates is very important in studying the relationship between the genotype and phenotype of CYP3A4.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26223917     DOI: 10.1007/s11596-015-1460-z

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  35 in total

1.  Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.

Authors:  M L Schrag; L C Wienkers
Journal:  Arch Biochem Biophys       Date:  2001-07-01       Impact factor: 4.013

2.  A genomic view of alternative splicing.

Authors:  Barmak Modrek; Christopher Lee
Journal:  Nat Genet       Date:  2002-01       Impact factor: 38.330

3.  Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

Authors:  Hiromi Fukushima-Uesaka; Yoshiro Saito; Hidemi Watanabe; Kisho Shiseki; Mayumi Saeki; Takahiro Nakamura; Kouichi Kurose; Kimie Sai; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Masafumi Kitakaze; Sotaro Hanai; Toshiharu Nakajima; Kenji Matsumoto; Hirohisa Saito; Yu-ichi Goto; Hideo Kimura; Masaaki Katoh; Kenji Sugai; Narihiro Minami; Kuniaki Shirao; Tomohide Tamura; Noboru Yamamoto; Hironobu Minami; Atsushi Ohtsu; Teruhiko Yoshida; Nagahiro Saijo; Yutaka Kitamura; Naoyuki Kamatani; Shogo Ozawa; Jun-ichi Sawada
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

Review 4.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

5.  Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.

Authors:  Cristina Rodríguez-Antona; Jane G Sayi; Lars L Gustafsson; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  2005-09-13       Impact factor: 3.575

6.  CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Authors:  Aleksandra Galetin; Kiyomi Ito; David Hallifax; J Brian Houston
Journal:  J Pharmacol Exp Ther       Date:  2005-03-22       Impact factor: 4.030

7.  Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.

Authors:  D Hickman; J P Wang; Y Wang; J D Unadkat
Journal:  Drug Metab Dispos       Date:  1998-03       Impact factor: 3.922

8.  Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.

Authors:  V A Eagling; J F Tjia; D J Back
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 9.  Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

Authors:  G G Gibson; N J Plant; K E Swales; A Ayrton; W El-Sankary
Journal:  Xenobiotica       Date:  2002-03       Impact factor: 1.908

Review 10.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

View more
  1 in total

1.  Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Authors:  Delores J Grant; Ani Manichaikul; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul D Terry; Xin-Qun Wang; Temitope O Keku; Cathrine Hoyo; Andrew Berchuck; Dale P Sandler; Jack A Taylor; Katie M O'Brien; Digna R Velez Edwards; Todd L Edwards; Alicia Beeghly-Fadiel; Nicolas Wentzensen; Celeste Leigh Pearce; Anna H Wu; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; Francesmary Modugno; Roberta Ness; Kirsten Moysich; Mary Anne Rossing; Jennifer A Doherty; Thomas A Sellers; Jennifer B Permuth-Way; Alvaro N Monteiro; Douglas A Levine; Veronica Wendy Setiawan; Christopher A Haiman; Loic LeMarchand; Lynne R Wilkens; Beth Y Karlan; Usha Menon; Susan Ramus; Simon Gayther; Aleksandra Gentry-Maharaj; Kathryn L Terry; Daniel W Cramer; Ellen L Goode; Melissa C Larson; Scott H Kaufmann; Rikki Cannioto; Kunle Odunsi; John L Etter; Ruea-Yea Huang; Marcus Q Bernardini; Alicia A Tone; Taymaa May; Marc T Goodman; Pamela J Thompson; Michael E Carney; Shelley S Tworoger; Elizabeth M Poole; Diether Lambrechts; Ignace Vergote; Adriaan Vanderstichele; Els Van Nieuwenhuysen; Hoda Anton-Culver; Argyrios Ziogas; James D Brenton; Line Bjorge; Helga B Salvensen; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Amanda Bruegl; Melissa Moffitt; Linda Cook; Nhu D Le; Angela Brooks-Wilson; Linda E Kelemen; Paul D P Pharoah; Honglin Song; Ian Campbell; Diana Eccles; Anna DeFazio; Catherine J Kennedy; Joellen M Schildkraut
Journal:  Cancer Med       Date:  2019-04-18       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.